MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Crinetics Pharmaceuticals Inc

Închisă

SectorSănătate

31.09 -5.84

Rezumat

Modificarea prețului

24h

Curent

Minim

30.74

Maxim

33.1

Indicatori cheie

By Trading Economics

Venit

-16M

-97M

Vânzări

361K

361K

Marjă de profit

-26,807.202

Angajați

437

EBITDA

-17M

-110M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+127.27% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-68M

3.1B

Deschiderea anterioară

36.93

Închiderea anterioară

31.09

Sentimentul știrilor

By Acuity

76%

24%

347 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 iul. 2025, 21:01 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 20:46 UTC

Câștiguri

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 iul. 2025, 20:39 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 20:36 UTC

Câștiguri

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 iul. 2025, 20:16 UTC

Achiziții, Fuziuni, Preluări

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 iul. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 iul. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 iul. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 iul. 2025, 18:24 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 iul. 2025, 18:19 UTC

Câștiguri

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 iul. 2025, 18:11 UTC

Achiziții, Fuziuni, Preluări

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 iul. 2025, 18:11 UTC

Câștiguri

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 iul. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 iul. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 iul. 2025, 16:28 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Energy & Utilities Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 16:04 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 iul. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 iul. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 iul. 2025, 15:47 UTC

Market Talk
Câștiguri

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparație

Modificare preț

Crinetics Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

127.27% sus

Prognoză pe 12 luni

Medie 72.5 USD  127.27%

Maxim 97 USD

Minim 36 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

10

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

30.39 / 33.46Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

347 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.